Poultry Vaccines Market Worth $3.2 Billion By 2026 | CAGR 6.2%

Poultry Vaccines Market Growth & Trends

The global poultry vaccines market size is expected to reach USD 3.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2% over the forecast period. Rising adoption of live poultry, increasing incidence of avian diseases, and rapid growth in poultry population are expected to drive the market over the forecast period. In addition, advent of new vaccines, such as Salmonella-vectored vaccines, which protect domesticated birds against necrotic enteritis is anticipated to provide a growth platform to this market.

Increasing adoption of poultry vaccines by research institutes and colleges, along with vaccination awareness programs, are factors fueling the growth of the market. For instance, in July 2019, the Veterinary College and Research Institute based in Madurai, India started vaccinating domesticated birds, predominantly chickens, to save farmers from suffering significant losses.

Technological advancements in poultry vaccines, rising demand for animal protein, concerns over food safety, animal welfare, and microbial resistance, increased focus on avian healthcare, and shift from treatment to prevention of diseases are some of the other factors anticipated to create growth opportunities in the poultry vaccines market.

North America is projected to dominate the market over the forecast period, with Asia Pacific likely to emerge as the fastest growing regional market over the forecast period. Europe is also a strong market, fueled by government initiatives for research and development activities and rapid improvement in animal husbandry practices.

Request a free sample copy or view report summary: 
Poultry Vaccines Market Report

Poultry Vaccines Market Report Highlights

• Increasing number of veterinary practitioners and technological advancements in the field are anticipated to create growth opportunities in the poultry vaccines market
• Attenuated vaccines accounted for the largest revenue share owing to their long lasting immunity and usage to prevent many avian diseases
• The infectious bronchitis disease segment is expected to exhibit lucrative growth over the forecast period as the disease is responsible for increased mortality among poultry and has a greater prevalence rate as compared to other avian diseases
• The breeder segment is expected to account for the largest revenue share due to increasing number of farm breeders involved in producing fertile eggs, thereby increasing productivity
• North America held the dominant share as of 2018 due to favorable government policies and new product launch by companies. For instance, in September 2017, MSD Animal Health introduced the HVT (herpes virus of turkeys) vaccine that protects birds from infectious bursal, Newcastle disease, and Mareck’s disease
• Some of the key companies in the market are Merck & Co. Inc.; Zoetis; Boehringer Ingelheim International GmbH; and Ceva.